Publication details
Imunoterapie u pacientů s karcinomem plic na MOÚ: účinnost, bezpečnost a náklady
| Title in English | Immunotherapy in patients with lung cancer at the Masaryk Memorial Cancer Institute: efficacy, safety and costs |
|---|---|
| Authors | |
| Year of publication | 2023 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | The aim of the analysis was to perform a comprehensive evaluation of the efficacy and cost of checkpoint inhibitors (pembrolizumab, nivolumab, durvalumab, atezolizumab and nivolumab in combination with ipilimumab) in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC) based on real clinical data. The analysis also includes a review of the incidence of immune-mediated adverse events in these patients. |
| Related projects: |